Bolt Biotherapeutics, Inc.
BOLTNASDAQHealthcareBiotechnology
Previous close
$3.665
+$0.465 · +14.53%
BOLT company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
52
Fair Value
Momentum
21
Weakening
Sentiment
40
Bearish
Risk resilience
28
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- William Quinn
- Listed since
- Feb 5, 2021
- Employees
- 23
Market position
Day range
Current $3.665
52-week range
Current $3.665
- Open
- $3.41
- Previous close
- $3.20
- Volume
- 65.14K
- 2.39× average
- Average volume
- 27.22K
- Average daily volume
- Market cap
- 7.04M USD
- Beta
- 1.08
- Market reference 1
- 50-day average
- $3.9587
- -7.42% below average
- 200-day average
- $4.7814
- -23.35% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 21.48M USD
- P/E (TTM)
- -0.23×
- P/B (TTM)
- 0.49×
- P/S (TTM)
- 1.5×
- EV / EBITDA
- -0.67×
- Earnings yield
- -326.30%
- Free cash flow yield
- -390.30%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 95.68%
- Operating margin
- -623.04%
- Net margin
- -611.47%
- Return on equity
- -125.92%
- Return on assets
- -58.81%
- Return on invested capital
- -67.72%
Financial health
- Debt / equity
- 1.71×
- Current ratio
- 3.59×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 7.7M USD | 7.69M USD | 7.88M USD | 5.73M USD | 1.26M USD |
| Cost of goods sold | 1.49M USD | — | 61.54M USD | 73.12M USD | 75.66M USD |
| Gross profit | 6.2M USD | 7.69M USD | −53.67M USD | −67.39M USD | −74.4M USD |
| Research and development | 28.53M USD | 57.47M USD | 61.54M USD | 73.12M USD | 75.66M USD |
| Selling, general, and administrative | 13.8M USD | 18.46M USD | 22.53M USD | 22.93M USD | 18.39M USD |
| Operating expenses | 40.84M USD | 80.74M USD | 22.53M USD | 22.93M USD | 18.39M USD |
| Interest income | 2.5M USD | 5.26M USD | 7M USD | 2.22M USD | 281K USD |
| Depreciation and amortization | 1.49M USD | 1.78M USD | 1.85M USD | 1.67M USD | 1.19M USD |
| Operating income | −34.63M USD | −73.05M USD | −76.2M USD | −90.32M USD | −92.79M USD |
| Net income | −33.38M USD | −63.12M USD | −69.2M USD | −88.1M USD | −98.59M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 4 misses, 2 met estimates
- Average EPS surprise
- -0.37%
- 11 comparable reports
- Latest EPS result
- -4.57
- Estimate -3.39 · Miss by 34.81%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$4.00
9.14% upsideRating distribution
8 ratingsRecent analyst actions
BOLT news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$0.32
2013 complete year+33.3% since 2012
$0.24
2,012
$0.32
2,013
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 29, 2014 | $0.0045Quarterly | — | Oct 2, 2014 |
Dividend | Jun 10, 2014 | $0.0045Quarterly | — | Jul 9, 2014 |
Dividend | Mar 3, 2014 | $0.0045Quarterly | — | Apr 2, 2014 |
Dividend | Dec 30, 2013 | $0.0045Quarterly | — | Jan 15, 2014 |
Dividend | Sep 3, 2013 | $0.0045Quarterly | — | Oct 3, 2013 |
Dividend | Jun 3, 2013 | $0.0035Quarterly | — | Jul 5, 2013 |
Ex-dividend Aug 29, 2014
$0.0045
Quarterly
Payment Oct 2, 2014
Ex-dividend Jun 10, 2014
$0.0045
Quarterly
Payment Jul 9, 2014
Ex-dividend Mar 3, 2014
$0.0045
Quarterly
Payment Apr 2, 2014
Ex-dividend Dec 30, 2013
$0.0045
Quarterly
Payment Jan 15, 2014
Ex-dividend Sep 3, 2013
$0.0045
Quarterly
Payment Oct 3, 2013
Ex-dividend Jun 3, 2013
$0.0035
Quarterly
Payment Jul 5, 2013
BOLT peers
ETFs holding BOLT
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research BOLTresearch.disclaimer